Sulfoalkyl ether cyclodextrin compositions
SAE-CD compositions are provided, along with methods of making and using the same. The SAE-CD compositions comprise a sulfoalkyl ether cyclodextrin having an absorption of less than 0.5 A.U. due to a drug-degrading agent, as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.
1. A sulfoalkyl ether cyclodextrin (SAE-CD) composition comprising a sulfoalkyl ether cyclodextrin having an average degree of substitution of 4.5 to 7.5, wherein the SAE-CD composition does not contain phosphate in an amount of 200 ppm or more and does not contain underivatized cyclodextrin in an amount of 0.5% wt. or more, and wherein the SAE-CD composition has an absorption of less than 0.5 A.U. as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length, wherein the amounts of the phosphate and the underivatized cyclodextrin are with respect to the SAE-CD composition; and
one or more active agents, wherein each active agent is independently selected from the group consisting of: an antifungal agent, an antipsychotic agent, an antineoplastic agent, an endocrine and metabolic agent, a gastrointestinal agent, and an anti-infective agent.
2. The SAE-CD composition of claim 1 , wherein the SAE-CD composition comprises an antifungal agent.
3. The SAE-CD composition of claim 2 , wherein the antifungal agent is selected from the group consisting of posaconazole, voriconazole, clotrimazole, ketoconazole, oxiconazole, sertaconazole, tetconazole, fluconazole, itraconazole, and miconazole.
4. The SAE-CD composition of claim 1 , wherein the SAE-CD composition comprises an antipsychotic agent.
5. The SAE-CD composition of claim 4 , wherein the antipsychotic agent is selected from the group consisting of clozapine, prochlorperazine, haloperidol, thioridazine, thiothixene, risperidone, trifluoperazine hydrochloride, chlorpromazine, aripiprazole, loxapine, loxitane, olanzapine, quetiapine fumarate, risperidone, and ziprasidone.
6. The SAE-CD composition of claim 1 , wherein the SAE-CD composition comprises a gastrointestinal agent.
7. The SAE-CD composition of claim 6 , wherein the gastrointestinal agent is selected from the group consisting of sucralfate, mesalamine, olsalazine sodium, balsalazide disodium, sulfasalazine, celecoxib, infliximab, and tegaserod maleate.
8. The SAE-CD composition of claim 1 , wherein the SAE-CD composition comprises an anti-infective agent.
9. The SAE-CD composition of claim 8 , wherein the anti-infective agent is selected from the group consisting of carbapenem, chloramphenicol, fluoroquinolones, spectinomycin, vancomycm, colistimethate sodium, polymyxin B sulfate, bacitracin, and metronidazole.
10. The SAE-CD composition of claim 1 , wherein the SAE-CD composition comprises an antineoplastic agent.
11. The SAE-CD composition of claim 10 , wherein the antineoplastic agent is selected from the group consisting of alkylating agents, antimetabolites, antimitotic agents, epipodophyllotoxins, antibiotics, hormones, enzymes, radiopharmaceuticals, platinum coordination complex, anthracenedione, substituted ureas, methylhydrazine derivatives, imidazotetrazine derivatives, cytoprotective agents, DNA topoisomerase inhibitors, biological response modifiers, retinoids, rexinoids, monoclonal antibodies, protein-tyrosine kinase inhibitors, porfimer sodium, mitotane (o, p′⋅ddd), and arsenic trioxide.
12. The SAE-CD composition of claim 1 , wherein the SAE-CD is a cyclodextrin of Formula 1:
wherein p is 4, 5 or 6, and R 1 is independently selected at each occurrence from —OH or —O—(C 2 -C 6 alkylene)-SO 3 − -T, wherein T is independently selected at each occurrence from pharmaceutically acceptable cations, provided that at least one R 1 is —OH and at least one R 1 is O—(C 2 -C 6 alkylene)-SO 3 − T.
13. The SAE-CD composition of claim 12 , wherein R 1 is independently selected at each occurrence from —OH or —O—(C 4 alkylene)-SO 3 − -T.
14. The SAE-CD composition of claim 13 , wherein -T is Na + at each occurrence.
15. The SAE-CD composition of claim 12 , wherein the pharmaceutically acceptable cation is H + , an alkali metal cation, an alkaline earth metal cation, an ammonium ion, and an amine cation.
16. The SAE-CD composition of claim 12 , wherein the pharmaceutically acceptable cation is an alkali metal cation selected from the group consisting of: Li + , Na + , and K + .
17. The SAE-CD composition of claim 12 , wherein the pharmaceutically acceptable cation is an alkaline earth metal cation selected from the group consisting of: Ca +2 and Mg +2 .
18. The SAE-CD composition of claim 12 , wherein the pharmaceutically acceptable cation is an amine cation selected from the group consisting of: (C1-C6)-alkylamine, piperidine, pyrazine, (C1-C6)-alkanolamine, ethylenediamine, and (C4-C8)-cycloalkanolamine.
19. The SAE-CD composition of claim 1 , wherein the average degree of substitution of the sulfoalkyl ether cyclodextrin is 6 to 7.1.
20. The SAE-CD composition of claim 1 , wherein the average degree of substitution of the sulfoalkyl ether cyclodextrin is 6.5 to 7.
21. The SAE-CD composition of claim 1 , wherein the composition comprises two or more different active agents.
22. The SAE-CD composition of claim 1 , wherein the endocrine and metabolic agent is selected from the group consisting of: sex hormones, uterine-active agents, bisphosphonates, antidiabetic agents, glucose elevating agents, corticosteroids, adrenocortical steroids, parathyroid hormone, thyroid drugs, growth hormones, posterior pituitary hormones, octreotide acetate, imiglucerase, calcitonin-salmon, sodium phenylbutyrate, betaine anhydrous, cysteamine bitartrate, sodium benzoate and sodium phenylacetate, bromocriptine mesylate, cabergoline, and agents for gout.
23. The SAE-CD composition of claim 1 , wherein the SAE-CD composition has an absorption of less than 0.2 A.U. as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.
24. The SAE-CD composition of claim 1 , wherein the SAE-CD composition has an absorption of less than 0.15 A.U. as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.
25. The SAE-CD composition of claim 1 , wherein the SAE-CD composition has an absorption of less than 0.1 A.U. as determined by UV/vis spectrophotometry at a wavelength of 245 nm to 270 nm for an aqueous solution containing 300 mg of the SAE-CD composition per mL of solution in a cell having a 1 cm path length.